AU2008239841B2 - N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles - Google Patents

N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles Download PDF

Info

Publication number
AU2008239841B2
AU2008239841B2 AU2008239841A AU2008239841A AU2008239841B2 AU 2008239841 B2 AU2008239841 B2 AU 2008239841B2 AU 2008239841 A AU2008239841 A AU 2008239841A AU 2008239841 A AU2008239841 A AU 2008239841A AU 2008239841 B2 AU2008239841 B2 AU 2008239841B2
Authority
AU
Australia
Prior art keywords
disorders
disorder
compound
iatrogenic
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008239841A
Other languages
English (en)
Other versions
AU2008239841A1 (en
Inventor
Hakan V. Wikstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of AU2008239841A1 publication Critical patent/AU2008239841A1/en
Assigned to IVAX International GmbH reassignment IVAX International GmbH Request for Assignment Assignors: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE
Application granted granted Critical
Publication of AU2008239841B2 publication Critical patent/AU2008239841B2/en
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH Request to Amend Deed and Register Assignors: IVAX International GmbH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008239841A 2007-04-12 2008-04-11 N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles Ceased AU2008239841B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
SE0700893-1 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (2)

Publication Number Publication Date
AU2008239841A1 AU2008239841A1 (en) 2008-10-23
AU2008239841B2 true AU2008239841B2 (en) 2013-07-18

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008239841A Ceased AU2008239841B2 (en) 2007-04-12 2008-04-11 N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Country Status (19)

Country Link
US (1) US9139525B2 (cg-RX-API-DMAC7.html)
EP (1) EP2146961B1 (cg-RX-API-DMAC7.html)
JP (1) JP5393654B2 (cg-RX-API-DMAC7.html)
CN (1) CN101711236B (cg-RX-API-DMAC7.html)
AU (1) AU2008239841B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810161A2 (cg-RX-API-DMAC7.html)
CA (1) CA2683719C (cg-RX-API-DMAC7.html)
CY (1) CY1115337T1 (cg-RX-API-DMAC7.html)
DK (1) DK2146961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2458592T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140380T1 (cg-RX-API-DMAC7.html)
IL (1) IL201401A (cg-RX-API-DMAC7.html)
MX (1) MX2009011020A (cg-RX-API-DMAC7.html)
NZ (1) NZ580856A (cg-RX-API-DMAC7.html)
PL (1) PL2146961T3 (cg-RX-API-DMAC7.html)
PT (1) PT2146961E (cg-RX-API-DMAC7.html)
RU (1) RU2470013C2 (cg-RX-API-DMAC7.html)
SI (1) SI2146961T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008127188A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2402713T3 (es) * 2008-11-24 2013-05-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derivados de 3-fenilo-3-metoxipirrolidina como moduladores de la transmisión catecolaminérgica cortical
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ ハンチントン病を治療するための高用量プリドピジンの使用
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN110505902B (zh) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗脆性x综合征的应用
ES2938546T3 (es) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
WO2001046146A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (cg-RX-API-DMAC7.html) 1962-10-10
CH481123A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ATE253364T1 (de) 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
NZ552409A (en) 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MXPA06013944A (es) * 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
SG169238A1 (en) * 2004-08-11 2011-03-30 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
DK1802573T3 (en) * 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
RU2394821C2 (ru) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-оксиды как пролекарства производных пиперазина и пиперидина
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP2009535374A (ja) * 2006-05-02 2009-10-01 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピリジルメチルピペラジンおよび−ピペリジン誘導体のｎ−オキサイド
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
CA2810092A1 (en) * 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US20130267552A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014052933A1 (en) * 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
WO2001046146A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BICKEL, M. H. et al., Pharmacol Rev, 1969, 21, 325-355 *
BRUCE, J. A. and MATZ, N., "Prodrugs to Reduce Presystemic Metabolism". Prodrugs. Challenges and Rewards Part 1. Ed. Valentino J. Stella, et al. New York: Springer, 2007. 339-355 *
Chemical Abstracts Accession No. 1979:22967 & Rajsner et al., Collection of Czechoslovak Chemical Communications, 1978, 43(7), pages 1760-1777 & CAS Registry Number 68351-27-9 *
TESTA, B., Current Opinion in Chemical Biology, vol 13, issue 3, 2009, pages 338-344 *

Also Published As

Publication number Publication date
JP5393654B2 (ja) 2014-01-22
CA2683719A1 (en) 2008-10-23
CA2683719C (en) 2015-07-14
SI2146961T1 (sl) 2014-08-29
IL201401A (en) 2015-10-29
EP2146961B1 (en) 2014-01-29
WO2008127188A1 (en) 2008-10-23
EP2146961A4 (en) 2011-08-03
DK2146961T3 (da) 2014-04-28
AU2008239841A1 (en) 2008-10-23
CN101711236B (zh) 2012-10-31
NZ580856A (en) 2011-11-25
CY1115337T1 (el) 2017-01-04
ES2458592T3 (es) 2014-05-06
RU2009141300A (ru) 2011-05-20
MX2009011020A (es) 2009-10-30
RU2470013C2 (ru) 2012-12-20
EP2146961A1 (en) 2010-01-27
IL201401A0 (en) 2010-05-31
CN101711236A (zh) 2010-05-19
HRP20140380T1 (hr) 2014-08-15
JP2010523651A (ja) 2010-07-15
PT2146961E (pt) 2014-04-30
US20100105736A1 (en) 2010-04-29
PL2146961T3 (pl) 2014-09-30
BRPI0810161A2 (pt) 2014-12-30
US9139525B2 (en) 2015-09-22

Similar Documents

Publication Publication Date Title
AU2008239841B2 (en) N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
HUP0203872A2 (hu) Helyettesített 4-(fenil-N-alkil)-piperazin és piperidinszármazékok, alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
JP5096654B2 (ja) ドーパミン神経伝達の新規のモジュレーター
JP5200288B2 (ja) 胃腸疾患および中枢神経系疾患の治療のための立体異性体化合物と方法
EP2038268A2 (en) Carbonylated (aza)cyclohexanes as dopamine d3 receptor ligands
RS20060317A (sr) Derivati n-/fenil(alkil-2-piperidin-2-il)metil/ benzamida postupak za njihovo dobijanje i njihova terapeutska primena
CA2180238A1 (en) Novel heterocyclic compounds
AU756484B2 (en) Muscarinic antagonists
AU2014268361B2 (en) Morphan and morphinan analogues, and methods of use
AU2007251663B2 (en) 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
HU185422B (en) Process for producing phenyl-azacycloalkanes
KR101176675B1 (ko) 테트라히드로이소퀴놀린 술폰아미드 유도체, 이의 제조, 및치료에서의 이의 용도
JP6173693B2 (ja) アリールピペラジンオピオイド受容体アンタゴニスト
KR101693128B1 (ko) 플루오린 치환된 고리형 아민계 화합물 및 이의제조방법, 약물 조성물 및 용도
PT90127B (pt) Processo para a preparacao de composicoes farmaceuticas com accao analgesica que contem 4-aril-4-piperidino (ou pirrolidino ou hexa-hidroazepino)-carbinois ou os seus analogos heterociclicos
BRPI0618971A2 (pt) compostos derivados de isoqionolina e benzo [h] isoqionolina, composição farmacêutica, utilização dos compostos e processo de preparo dos compostos
KR20110009065A (ko) 신규의 피페리딘 화합물, 이들의 제조 방법 및 이를 함유한 약제학적 조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IVAX INTERNATIONAL GMBH

Free format text: FORMER APPLICANT(S): NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired